Skip to content
Search

Latest Stories

FSB and Bank of England join hands to tackle counterfeit notes in run up to Christmas

FSB and Bank of England join hands to tackle counterfeit notes in run up to Christmas

Businesses that accept counterfeits can be repeatedly targeted, warns FSB, while encouraging its members to join the Bank of England’s Banknote Checking Scheme  

The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes.


Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB.

By becoming a Strategic Partner of the Bank of England’s Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts.

The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.

Martin McTague, National Chair at the Federation of Small Businesses, believes that, through this new strategic partnership with the Bank of England, they would be able to help equip businesses with the tools to tackle counterfeit notes.

He said: “FSB views cash as an essential part of the economy despite an increase in digital payments. Many small businesses rely heavily on cash; it provides a form of commerce to less digitalised businesses, acts as a check on pricing fees of card transactions and as a backup for when digital methods go down. For a quarter of our members, cash is still the number one customer payment method.”

Though the number of counterfeits being accepted has reduce due to the introduction of new polymer notes and law enforcement successes, businesses across the UK are still being defrauded by counterfeiters, the FSB said.

It has also warned that businesses that accept counterfeits can be repeatedly targeted by criminals, who may try to buy a low-value item using a higher counterfeit value note such as a £20 or £50.

Sarah John, Chief Cashier and Executive Director Banking at the Bank of England, is also hopeful that this new partnership will help reduce losses to businesses.

“The continued success of the Scheme relies on key industry stakeholders such as FSB to raise awareness and to help us ensure the Scheme continues to provide what helps their members the most,” she added.

Small businesses can sign up to the Banknote Checking Scheme for free at https://www.bankofengland.co.uk/banknotes/banknote-checking-scheme

The King Charles III banknotes is expected to enter circulation in mid-2024, but there are no plans to withdraw polymer banknotes that feature the portrait of Late Queen Elizabeth II. The first polymer notes were issued as £5 notes in 2016.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less